In recent 20 years, TNF-α is one of the predominant targets for the treatment of RA, and many anti-TNF-α drugs, including adalimumab, infliximab, and etanercept, have been successfully developed (Feldmann and Maini, 2001; Bossaller and Rothe, 2013). This evidence concerns the gene TNF and rheumatoid arthritis.